To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Recruiting · NCT06647550 · Interventional (participants receive a specific treatment) · Lead sponsor: Hyundai Pharm
View the official record on ClinicalTrials.gov →Interventions studied
HD-6277 100mgHD-6277 25mgHD-6277 50mgPlacebo
What this trial is about
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Who can take part
Age range
19 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening.
Exclusion criteria
- Type 1 diabetes or another immune-mediated diabetes syndrome
- BMI: \> 40 kg/m2
- C-peptide: \< 0.5ng/mL
Where it is running
1 location listed.
- Korea University Anam Hospital - Seoul, South Korea